Acute Clinical Trials in Beijing, Beijing Municipality
118 recruitingBeijing, Beijing Municipality, China
Showing 1–20 of 118 trials
Recruiting
Phase 1Phase 2
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
B Cell Precursor Acute Lymphoblastic Leukemia
Amgen281 enrolled109 locationsNCT04521231
Recruiting
Phase 1Phase 2
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
Myeloid MalignancyRelapsed/Refractory Acute Myeloid Leukaemia
Ascentage Pharma Group Inc.682 enrolled12 locationsNCT04501120
Recruiting
Phase 1
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
Acute Myelogenous LeukemiaMyelodysplastic Syndromes (MDS)
Beijing InnoCare Pharma Tech Co., Ltd.266 enrolled18 locationsNCT06656494
Recruiting
Phase 1Phase 2
TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
Acute Lymphocytic Leukemia
Chinese PLA General Hospital30 enrolled6 locationsNCT06481735
Recruiting
Not Applicable
Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients
Acute Lymphoblastic Leukemia, in RelapseB-cell Acute Lymphoblastic LeukemiaRefractory Acute Lymphoid Leukemia
Beijing GoBroad Hospital353 enrolled1 locationNCT06343090
Recruiting
Phase 1Phase 2
Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies
T-cell Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic Leukemia+1 more
Beijing GoBroad Hospital80 enrolled4 locationsNCT06316427
Recruiting
Phase 1Phase 2
A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies
Acute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic LeukemiaT-cell Malignancies+1 more
Beijing GoBroad Hospital54 enrolled4 locationsNCT07070323
Recruiting
Phase 1
A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Sichuan Baili Pharmaceutical Co., Ltd.130 enrolled8 locationsNCT05924750
Recruiting
Phase 3
A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia
Acute Myeloid Leukemia
Hutchmed316 enrolled53 locationsNCT06387069
Recruiting
Digital Early Warning System for Acute Lung Injury in Liver Surgery
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)Acute Lung Injury(ALI)Liver Cirrhosis+4 more
Beijing Tsinghua Chang Gung Hospital4,000 enrolled1 locationNCT07070362
Recruiting
Phase 2
A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients
Acute Myeloid LeukemiaFirst Line Therapy
Chinese PLA General Hospital160 enrolled1 locationNCT06928376
Recruiting
Phase 1Phase 2
Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML
Acute Myeloid LeukemiaAMLAML, Adult+1 more
Essen Biotech85 enrolled1 locationNCT06420063
Recruiting
Phase 1
A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.
Acute Myeloid Leukemia (AML)Myelodysplastic Syndromes (MDS)
Ascentage Pharma Group Inc.102 enrolled14 locationsNCT04275518
Recruiting
Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
B-cell Acute Lymphoblastic Leukemia
Juventas Cell Therapy Ltd.200 enrolled10 locationsNCT06450067
Recruiting
Phase 2
VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS
Minimal Residual DiseaseMyelodysplastic SyndromesRefractory Acute Myeloid Leukemia+1 more
Beijing 302 Hospital67 enrolled1 locationNCT06536959
Recruiting
Phase 2
A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic LeukemiaRelapsed Pediatric ALL
Chongqing Precision Biotech Co., Ltd100 enrolled10 locationsNCT05334823
Recruiting
Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction
Acute LeukemiaMDSMDS/MPN+1 more
Peking University People's Hospital300 enrolled1 locationNCT06211166
Recruiting
Phase 2
CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia
Diffuse Large B Cell LymphomaB-cell Acute Lymphoblastic LeukemiaB-cell Lymphoma
Beijing Tongren Hospital100 enrolled1 locationNCT06081478
Recruiting
Not Applicable
Clinical Study of DC-AML Cells in the Treatment of Acute Myeloid Leukemia
Acute Myeloid Leukemia
Affiliated Hospital to Academy of Military Medical Sciences20 enrolled1 locationNCT05000801
Recruiting
Phase 2Phase 3
Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT
Stem Cell Transplant ComplicationsLeukemia, Myeloid, AcuteLeukemia Relapse
Peking University People's Hospital55 enrolled1 locationNCT03793517